Erin Harris
Click here to email Erin.
Erin Harris is chief editor of Cell & Gene and a contributing editor to Life Science Leader magazine. She studied English and psychology at Lafayette College and has 20+ years of experience in B2B publishing. Erin spent 10 years covering and reporting on the adoption of information technology from a B2B perspective. She’s written on technology topics ranging from Big Data and analytics to security and e-commerce. In each case, her reporting centered on innovations that improved operational efficiencies, fostered interdepartmental collaboration, or enhanced supply chains. Currently, she writes actionable information for professionals involved in the development and commercialization of cell and gene therapies. She covers the entire product lifecycle from basic research to commercialization. Erin has interviewed executives from Fortune 500 as well as startups. She has moderated panel discussions and has spoken at numerous industry events from large conferences to niche forums.
ARTICLES BY ERIN HARRIS
-
![scientist with microscope-GettyImages-1181392325]( "Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN")
Ferring Builds A Global Gene Therapy Manufacturing Network Around ADSTILADRIN5/16/2025Ferring Pharmaceuticals has built a global manufacturing and support network around its flagship gene therapy, ADSTILADRIN, enabling scalable production, provider education, patient access, and real-world data collection to ensure sustainable and widespread adoption.
-
![23_12_CGPodcast_450x300_Ep99]( "Atsena Therapeutics Advances Gene Therapy For XLRS")
Atsena Therapeutics Advances Gene Therapy For XLRS5/13/2025Atsena Therapeutics exemplifies the field’s growing shift toward non-oncology indications with its targeted gene therapy for X-linked retinoschisis, a rare inherited retinal disorder with no approved treatments.
-
![The Next Step-GettyImages-2043649530]( "Navigating CGT Biotech's Financial Headwinds And The Path Forward")
Navigating CGT Biotech's Financial Headwinds And The Path Forward4/24/2025Dr. Ali Pashazadeh, Founder of Treehill Partners shares how CGT companies can navigate today’s biotech downturn by embracing integrated strategies, disciplined capital use, and bold leadership willing to rethink traditional models across innovation, manufacturing, and commercialization.
-
![arrows going up, target-GettyImages-1295651837]( "How Cynata Therapeutics is Unlocking the Power of iPSCs to Transform Regenerative Medicine")
How Cynata Therapeutics is Unlocking the Power of iPSCs to Transform Regenerative Medicine4/11/2025Cynata Therapeutics is pioneering a scalable, iPSC-based platform to produce consistent, high-quality MSCs that are showing strong clinical promise across multiple indications, including GvHD, diabetic foot ulcers, and osteoarthritis.
-
![25_03_CGL_1200x1200]( "Emerging Technologies For Cell Therapy Manufacturing")
Emerging Technologies For Cell Therapy Manufacturing4/7/2025This summary of the Cell & Gene Live, Emerging Technologies in Cell Therapy Manufacturing, explains why automation, robotics, AI, and digital tools offer a clear path to scalable, efficient, and patient-centric manufacturing.
-
![GettyImages-2156834696-light-bulb-innovation-idea-creativity]( "Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center")
Collaboration Leads To CGT Progress At Astellas' West Coast Innovation Center3/13/2025Yoshi Shitaka, outgoing CSO and Richard Wilson, SVP, Primary Focus Lead (Genetic Regulation) at Astellas share how the company's West Coast Innovation Center serves as a central hub for AI, digital transformation, and more.
-
![Sickle-cell disease-GettyImages-964040238]( "Tessera Therapeutics Advances In Vivo Gene Therapy For SCD")
Tessera Therapeutics Advances In Vivo Gene Therapy For SCD1/30/2025Tessera Therapeutics' CSO, Michael Holmes, Ph.D., shares information on the company's Gene Writers for sickle cell disease (SCD) and how their work has garnered investment from of the Bill & Melinda Gates Foundation to support their efforts.
-
![year 2025 growth-GettyImages-2153623617]( "2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC")
2025 Outlook For CGT: Focus On Non-Oncology Indications, In Vivo Gene Editing, And POC12/4/2024Leaders from Kiji Therapeutics, Precision Biosciences, and Orgenesis weigh in on what will likely accelerate the development of novel treatments, potentially revolutionizing patient care across a wider range of diseases and bringing the promise of personalized medicine closer to reality in 2025 and beyond.
-
![Medical healthcare autoimmune disease-GettyImages-1449402295]( "CD70 & Autoimmune Diseases")
CD70 & Autoimmune Diseases11/26/2024Allogene Therapeutics' Dr. Zachary Roberts shares the clinical-stage biotech's rationale behind selecting CD70 as a target for activated T cells in autoimmune diseases.
-
![23_12_CGPodcast_1280x720_Ep87]( "Neogene's Focus On Off-The-Shelf TCR Therapies")
Neogene's Focus On Off-The-Shelf TCR Therapies10/31/2024This recap of Episode 87 of Cell & Gene: The Podcast shares Neogene Therapeutics' Carsten Linnemann, Ph.D.'s take on why "off-the-shelf" will make t-cell receptor therapies more accessible to patients.
